Industry

BERWYN, Pa.–(BUSINESS WIRE)–#pharma—Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that Jeffrey Gudin, MD, will present a poster at the World Congress of World Institute of Pain entitled, “Enkephalin as … [Read more…]

Tisch MS Research Center of New York identifies key protein that causes motor disability and motor neuron degeneration in sALS, paving the way for first-of-its-kind treatment target for the disease NEW YORK–(BUSINESS WIRE)–The Larry G. Gluck Division of ALS Research, located at the Tisch MS Research Center of New York, has published research in Brain … [Read more…]

BETHESDA, Md.–(BUSINESS WIRE)–ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced the appointment of Peter Greenleaf to its board of directors. Mr. Greenleaf, a seasoned industry executive with nearly 30 years of experience leading successful life sciences companies, is currently the president, chief executive officer and member … [Read more…]

HOUSTON–(BUSINESS WIRE)–Tachyon Therapeutics, Inc. (“Tachyon” or “the Company”), a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to develop TACH101 for the treatment of advanced solid tumors. “The approval of this IND marks a … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–#LymeDisease–The National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care … [Read more…]

Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today … [Read more…]

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:45 p.m. ET in Boston, MA. … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, today presented research describing the chemical structure of NDI-034858, the company’s investigational oral allosteric TYK2 (tyrosine kinase 2) inhibitor now in two Phase 2b clinical studies for moderate-to-severe plaque psoriasis and active … [Read more…]

N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune responses TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced favorable preliminary results from its ongoing Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile … [Read more…]

Results will further underscore efficacy and safety of IMFINZI®, TAGRISSO®, and LYNPARZA® across multiple cancers with high unmet need ENHERTU data will reinforce its transformative potential in HER2-targetable cancers New data for MEDI5752 will advance the science of next-generation immunotherapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present new data supporting its ambition to redefine cancer care at … [Read more…]